Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
CVS Caremark Settles with FTC Over Drug Rebate Practices, Agrees to Count TrumpRx Purchases Toward Deductibles
00

CVS Caremark Settles with FTC Over Drug Rebate Practices, Agrees to Count TrumpRx Purchases Toward Deductibles

Apr 20, 2026

CVS Health's Caremark has finalized a settlement with the FTC on July 14, 2026, to curb after-market drug rebates and allow clients to opt out of rebate models. The agreement, mirroring a prior Cigna deal, requires CVS to count TrumpRx.gov purchases toward deductibles once supporting regulations are established. FTC Chairman Andrew Ferguson expects the settlement to save consumers billions of dollars. TrumpRx.gov, launched in February 2026, offers discounted weight-loss and other drugs but previously operated outside insurance.

FTC settlement with CVS Caremark

  • ▪The settlement between CVS Caremark and the Federal Trade Commission mirrors a similar agreement reached between the agency and Cigna earlier in 2026
  • ▪CVS Health's Caremark finalized a settlement with the U.S. Federal Trade Commission on July 14, 2026, to address drug rebate practices

Rebate opt-out for clients

  • ▪Drug rebates are paid by drugmakers to pharmacy benefit managers and may or may not be passed on to plan sponsors or consumers
  • ▪The Federal Trade Commission settlement requires CVS Caremark to provide health plan clients with an option to opt out of rebate-based payment models

After-market rebate curbs

  • ▪The Federal Trade Commission settlement obliges CVS Caremark to curb its use of after-market discounts known as rebates
  • ▪Critics argue that after-market drug rebate practices contribute to high drug costs for consumers

TrumpRx deductible counting requirement

  • ▪The requirement to count TrumpRx purchases toward deductibles will take effect once regulations are in place to facilitate the TrumpRx program
  • ▪The settlement requires CVS Caremark to count consumer purchases from the TrumpRx website toward deductibles on some health plans

Consumer drug price savings

  • ▪Federal Trade Commission Chairman Andrew Ferguson stated that the settlement is expected to bring billions of dollars in savings on drug prices
  • ▪President Donald Trump launched TrumpRx.gov in February 2026 to offer discounted generic and branded drugs, focusing on weight-loss medications

TrumpRx platform limitations

  • ▪The out-of-insurance operation of TrumpRx.gov has limited its value for some American consumers who must meet health plan deductibles
  • ▪TrumpRx.gov operates outside of insurance by sending cash-pay customers directly to drugmaker websites for discounted drugs

4 sources

Tradersunion
CVS Caremark settles FTC case over drug rebates and TrumpRx deductible credits
View source article
Boursorama
CVS conclut un accord avec la FTC et accepte de prendre en compte les achats de médicaments TrumpRx dans le cadre de l'assurance
View source article
Devdiscourse
CVS Health's Landmark Settlement with FTC to Slash Drug Costs | Health
View source article
Investing
CVS settles with FTC, agrees to count TrumpRx drug purchases towards insurance By Reuters
View source article

Featured stories

Trump Signs Executive Order to Expedite Psychedelic Drug Review and Reclassification

Apr 18, 2026 · 3 sources

US uninsured rate holds steady at 8% in 2025, but could rise amid Trump administration health policy changes

May 28, 2026 · 2 sources

U.S. Hantavirus Response Hampered by Trump Administration Cuts to CDC and Public Health Infrastructure

May 9, 2026 · 3 sources

Trump Administration Announces 100% Tariffs on Brand-Name Drugs with Carveouts

Apr 3, 2026 · 2 sources

Share your thoughts

Should pharmacy benefit managers be banned from receiving drug rebates?

Story comments

Loading comments…

Share your thoughts

Should pharmacy benefit managers be banned from receiving drug rebates?

Related entities

United States

People Involved

Donald Trump

Topics

Drug pricingUS healthcare regulationGovernment and Regulatory PolicyHealthcare Access and InsurancePharmaDrug Pricing and Access

Featured stories

Trump Signs Executive Order to Expedite Psychedelic Drug Review and Reclassification

Apr 18, 2026 · 3 sources

US uninsured rate holds steady at 8% in 2025, but could rise amid Trump administration health policy changes

May 28, 2026 · 2 sources

U.S. Hantavirus Response Hampered by Trump Administration Cuts to CDC and Public Health Infrastructure

May 9, 2026 · 3 sources

Trump Administration Announces 100% Tariffs on Brand-Name Drugs with Carveouts

Apr 3, 2026 · 2 sources